A new trading day began on Friday, with Moderna Inc (NASDAQ: MRNA) stock price down -6.09% from the previous day of trading, before settling in for the closing price of $51.87. MRNA’s price has ranged from $22.28 to $55.20 over the past 52 weeks.
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -42.94%. Meanwhile, its annual earnings per share averaged 14.59%. With a float of $357.38 million, this company’s outstanding shares have now reached $391.00 million.
Moderna Inc (MRNA) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Moderna Inc is 8.54%, while institutional ownership is 69.70%. The most recent insider transaction that took place on Dec 11 ’25, was worth 703,306. In this transaction Director of this company sold 23,853 shares at a rate of $29.48, taking the stock ownership to the 3,924 shares. Before that another transaction happened on Dec 11 ’25, when Company’s Affiliate proposed sale 23,853 for $29.49, making the entire transaction worth $703,306.
Moderna Inc (MRNA) Recent Fiscal highlights
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -2.91 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -2.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 14.59% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 20.29% during the next five years compared to -42.94% drop over the previous five years of trading.
Moderna Inc (NASDAQ: MRNA) Trading Performance Indicators
Here are Moderna Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.73. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.53.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -8.06, a number that is poised to hit -2.58 in the next quarter and is forecasted to reach -6.72 in one year’s time.
